The stock of Can-Fite Biopharma Ltd ADR (CANF) has seen a 22.92% increase in the past week, with a 22.92% gain in the past month, and a -8.94% decrease in the past quarter. The volatility ratio for the week is 4.10%, and the volatility levels for the past 30 days are at 4.42% for CANF. The simple moving average for the last 20 days is 17.00% for CANF stock, with a simple moving average of -7.12% for the last 200 days.

Is It Worth Investing in Can-Fite Biopharma Ltd ADR (AMEX: CANF) Right Now?

The 36-month beta value for CANF is also noteworthy at 1.33. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


The average price estimated by analysts for CANF is $12.00, which is $9.64 above than the current price. The public float for CANF is 4.08M, and at present, short sellers hold a 0.45% of that float. The average trading volume of CANF on November 21, 2023 was 7.90K shares.

CANF) stock’s latest price update

The stock price of Can-Fite Biopharma Ltd ADR (AMEX: CANF) has surged by 17.71 when compared to previous closing price of 2.01, but the company has seen a 22.92% gain in its stock price over the last five trading sessions. PennyStocks reported 2023-11-21 that As retail investors seek explosive returns, penny stocks remain enticing potential opportunities capable of massive short-term gains. However, the considerable risks of these cheap equities also highlight the need for due diligence.

Analysts’ Opinion of CANF

Many brokerage firms have already submitted their reports for CANF stocks, with Maxim Group repeating the rating for CANF by listing it as a “Buy.” The predicted price for CANF in the upcoming period, according to Maxim Group is $7 based on the research report published on August 11, 2017 of the previous year 2017.

CANF Trading at 3.71% from the 50-Day Moving Average

After a stumble in the market that brought CANF to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.63% of loss for the given period.

Volatility was left at 4.42%, however, over the last 30 days, the volatility rate increased by 4.10%, as shares surge +12.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.54% lower at present.

During the last 5 trading sessions, CANF rose by +14.58%, which changed the moving average for the period of 200-days by -45.00% in comparison to the 20-day moving average, which settled at $2.03. In addition, Can-Fite Biopharma Ltd ADR saw -61.50% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for CANF

Current profitability levels for the company are sitting at:

The net margin for Can-Fite Biopharma Ltd ADR stands at -1255.93. The total capital return value is set at -110.95, while invested capital returns managed to touch -112.41. Equity return is now at value -116.20, with -75.58 for asset returns.

Based on Can-Fite Biopharma Ltd ADR (CANF), the company’s capital structure generated 1.39 points at debt to equity in total, while total debt to capital is 1.37. Total debt to assets is 0.67, with long-term debt to equity ratio resting at 0.31. Finally, the long-term debt to capital ratio is 0.31.

When we switch over and look at the enterprise to sales, we see a ratio of 1.39, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 17.27 and the total asset turnover is 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.66.


In summary, Can-Fite Biopharma Ltd ADR (CANF) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.